Trials / Completed
CompletedNCT04171414
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Moderate to Severe Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Celltrion · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Detailed description
CT-P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal antibody that is being developed as a similar biological medicinal product to Humira. The purpose of this study is to evaluate usability of subcutaneous auto-injector of CT-P17 in patients with moderate to severe rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CT-P17 SC AI (adalimumab) | Subcutaneous Injection of Adalimumab 40mg once every two weeks |
Timeline
- Start date
- 2019-09-09
- Primary completion
- 2019-11-04
- Completion
- 2020-04-24
- First posted
- 2019-11-20
- Last updated
- 2021-11-17
- Results posted
- 2021-11-17
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT04171414. Inclusion in this directory is not an endorsement.